COVID-19Regulatory

Coronavirus pandemic in the U.S.

May 21, 2020 / By Melissa Macaya, Mike Hayes, Meg Wagner and Zamira Rahim, CNN

Vaccine doctor says seniors must be included in studies.

Seniors must be included in therapeutic and vaccine studies, because they have a weaker immune system and respond differently to medicines, Dr. Mark Mulligan, director of Infectious Diseases and Immunology at the Langone Vaccine Center, told senators today.

Speaking before Senate Aging Committee hearing on “Caring for Seniors Amid the Covid-19 Crisis,” Mulligan said the participation of older adults in studies is already common practice in things like the flu vaccine. 

“Having a stronger vaccine, one with an adjuvant, one with a higher dose may be necessary for Covid-19 and seniors as well,” Mulligan

Adjuvants are ingredients added to vaccines to help them work better, according to the US Centers for Disease Control and Prevention.   

“We also want to be sure that treatments are tolerated well and are safe in seniors; their system is different. So we need to be sure to include seniors in our treatments, as well as our vaccine studies,” Mulligan said.  

READ THE REST HERE

Print Friendly, PDF & Email
Tags

Mike Adams

Mike Adams is a medical device sales leader with extensive clinical experience in spine and biologics and a nationwide distribution network built over the last 10+ years in the industry. He has held various leadership positions in healthcare and device including Distributor Partner, Hospital COO and Spine VP of Sales. He currently leads the commercialization strategy for OrthoSpine Partners and is a Distributor Principal at Novel Medical. Because of his unique career path, Mike has the ability to see the healthcare business from multiple perspectives making him passionate about building strategic partnerships that help reduce overall costs, drive innovation, and cultivate growth for new markets.

Related Articles

Back to top button
Close